These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

109 related items for PubMed ID: 22350324

  • 1. Lateral rectus muscle paralysis induced by ribavirin and pegylated interferon-α2a in a patient with HIV/HCV co-infection.
    Mellon G, Stitou H, Aoun O, Tubiana R, Thibault V, Valantin MA, Bricaire F.
    J Infect Chemother; 2012 Dec; 18(6):937-8. PubMed ID: 22350324
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Modifications of haematological series in patients co-infected with human immunodeficiency virus and hepatitis C virus during treatment with interferon and ribavirin: differences between pegylated and standard interferon.
    Arizcorreta A, Brun F, Fernández-Gutiérrez C, García Juárez R, Guerrero F, Pérez-Guzmán E, Girón-González JA.
    Clin Microbiol Infect; 2004 Dec; 10(12):1067-74. PubMed ID: 15606633
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Effect of an induction period of pegylated interferon-α2a and ribavirin on early virological response in HIV-HCV-coinfected patients: results from the CORAL-2 study.
    Tural C, Solà R, Alvarez NP, Moltó J, Sánchez M, Zamora AM, Ornelas A, Laguno M, González J, von Wichmann MÁ, Téllez MJ, Paredes R, Clotet B, CORAL-2 study group.
    Antivir Ther; 2011 Dec; 16(6):833-41. PubMed ID: 21900715
    [Abstract] [Full Text] [Related]

  • 6. Pegylated interferon-α2a with or without low-dose ribavirin for treatment-naive patients with hepatitis C virus genotype 1 receiving hemodialysis: a randomized trial.
    Liu CH, Huang CF, Liu CJ, Dai CY, Liang CC, Huang JF, Hung PH, Tsai HB, Tsai MK, Chen SI, Lin JW, Yang SS, Su TH, Yang HC, Chen PJ, Chen DS, Chuang WL, Yu ML, Kao JH.
    Ann Intern Med; 2013 Dec 03; 159(11):729-38. PubMed ID: 24297189
    [Abstract] [Full Text] [Related]

  • 7. Is combination therapy interferon and ribavirin in patients with chronic hepatitis C infection toxic for eyes?
    Mousa N, Besheer T, Gad Y, Elbendary A, Mokbel T, Abdel-Aziz A.
    J Ocul Pharmacol Ther; 2013 Apr 03; 29(3):345-8. PubMed ID: 23113644
    [Abstract] [Full Text] [Related]

  • 8. Commentary: efficacy and safety of ribavirin plus pegylated interferon-alpha in geriatric patients with chronic hepatitis C - authors' reply.
    Hu CC, Chien RN.
    Aliment Pharmacol Ther; 2013 Feb 03; 37(4):492. PubMed ID: 23336679
    [No Abstract] [Full Text] [Related]

  • 9. [Pegylated interferon and ribavirin associated retinopathy in patients with hepatitis C].
    Burgueño-Montañés C, Pérez-Álvarez R.
    Arch Soc Esp Oftalmol; 2011 Jun 03; 86(6):193-5. PubMed ID: 21767697
    [Abstract] [Full Text] [Related]

  • 10. Chronic hepatitis C in patients with HIV/AIDS: a new challenge in antiviral therapy.
    Bräu N.
    J Antimicrob Chemother; 2005 Dec 03; 56(6):991-5. PubMed ID: 16308419
    [Abstract] [Full Text] [Related]

  • 11. Efficacy of pegylated interferon and ribavirin for retreatment of chronic HCV infection in HIV co-infected patients failing a previous standard interferon-based regimen.
    Crespo M, Mira JA, Pineda JA, Van den Eynde E, Ríos-Villegas MJ, Collado A, Girón-González JA, López-Cortés LF, González-Serrano M, Rivero A, Merino D, Esteban JI.
    J Antimicrob Chemother; 2008 Oct 03; 62(4):793-6. PubMed ID: 18567911
    [Abstract] [Full Text] [Related]

  • 12. Development of ocular myasthenia during pegylated interferon and ribavirin treatment for chronic hepatitis C.
    Kang HM, Park MJ, Hwang JM, Kim JW, Jeong SH.
    Korean J Hepatol; 2009 Jun 03; 15(2):209-15. PubMed ID: 19581773
    [Abstract] [Full Text] [Related]

  • 13. Efficacy and safety of ribavirin plus pegylated interferon alfa in geriatric patients with chronic hepatitis C.
    Hu CC, Lin CL, Kuo YL, Chien CH, Chen SW, Yen CL, Lin CY, Chien RN.
    Aliment Pharmacol Ther; 2013 Jan 03; 37(1):81-90. PubMed ID: 23121150
    [Abstract] [Full Text] [Related]

  • 14. Efficacy and safety of pegylated interferon plus ribavirin in HIV and hepatitis C virus-coinfected patients with advanced immunosuppression.
    Mira JA, Gutiérrez-Valencia A, Gil Ide L, Merino D, Rivero A, Ríos-Villegas MJ, Delgado M, González-Serrano M, Collado A, Torres-Tortosa M, Omar M, López-Ruz MA, Macías J, Arponen S, Pineda JA.
    Clin Infect Dis; 2009 Oct 15; 49(8):e84-91. PubMed ID: 19772388
    [Abstract] [Full Text] [Related]

  • 15. Ischemic colitis during pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C.
    Leung Y, Urbanski SJ, Schindel L, Myers RP.
    Can J Gastroenterol; 2006 Oct 15; 20(10):661-3. PubMed ID: 17066158
    [Abstract] [Full Text] [Related]

  • 16. Comparison of high ribavirin induction versus standard ribavirin dosing, plus peginterferon-α for the treatment of chronic hepatitis C in HIV-infected patients: the PERICO trial.
    Labarga P, Barreiro P, da Silva A, Guardiola JM, Rubio R, Aguirrebengoa K, Miralles P, Portu J, Téllez MJ, Morano L, Castro A, Pineda JA, Terrón A, Hernández-Quero J, Mariño A, Ríos MJ, Echeverría S, Asensi V, Vispo E, Soriano V, PERICO Study Group.
    J Infect Dis; 2012 Sep 15; 206(6):961-8. PubMed ID: 22807523
    [Abstract] [Full Text] [Related]

  • 17. Pegylated interferon (alone or with ribavirin) for chronic hepatitis C in haemodialysis population.
    Espinosa M, Hernàndez J, Arenas MD, Carnicer F, Caramelo C, Fabrizi F.
    Kidney Blood Press Res; 2015 Sep 15; 40(3):258-65. PubMed ID: 25997572
    [Abstract] [Full Text] [Related]

  • 18. [Pegylated-interferon alpha plus ribavirin-induced subacute thyroiditis in chronic hepatitis C].
    Abellán Galiana P, Pérez-Lázaro A, Aguilera Sancho-Tello V, Merino Torres JF, Berenguer Haym M, Piñón Sellés F.
    Endocrinol Nutr; 2009 Mar 15; 56(3):136-9. PubMed ID: 19627727
    [Abstract] [Full Text] [Related]

  • 19. Premature treatment discontinuation in HIV/HCV-coinfected patients receiving pegylated interferon plus weight-based ribavirin.
    Soriano V, Miralles C, Berdún MA, Losada E, Aguirrebengoa K, Ocampo A, Arazo P, Cervantes M, de los Santos I, San Joaquín I, Echeverria S, Galindo MJ, Asensi V, Barreiro P, Sola J, Hernandez-Burruezo JJ, Guardiola J, Blanco F, Martin-Carbonero L, García-Samaniego J, Nuñez M, PRESCO Study Group.
    Antivir Ther; 2007 Mar 15; 12(4):469-76. PubMed ID: 17668555
    [Abstract] [Full Text] [Related]

  • 20. [APRICOT Study evaluated. Surprisingly high virologic response in HIV-HCV coinfection].
    MMW Fortschr Med; 2004 Apr 26; 146 Spec No 1():74-5. PubMed ID: 15373058
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.